Design Therapeutics, Inc. (DSGN)
Designs drugs to treat genetic diseases caused by repeated DNA sequences.
$11.87-0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+210.7%
The outlook
DSGN is trading at $11.87, positioned roughly midway in its 52-week range with mixed momentum against its moving averages. Analyst coverage leans bullish, with an average price target implying roughly 77% upside from current levels. The overall sentiment shows a moderately positive lean, though the stock's recent price action remains choppy.
What’s behind the score
Price trendMixed vs its moving averages
52-week range60% of the way from its 52-week low to high
Price targetAvg target +77% vs current price
Analyst price target
~12-month · 6 analysts$21.00average target+76.9% vs now
Now $11.87
Low $20.00High $22.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$741.4M
52-wk high
$17.25
52-wk low
$3.76
50-day avg
$12.37
200-day avg
$10.51
Trailing P/E
—